

Dr. Tim F. Wolff, Prof. Dr. Dr. Knut A. Grötz

Risikopatienten in der Zahnmedizin

Interaktion unterschiedlichster Medikamente

1. United Nations. *World Population Prospects: The 2017 Revision*. 2017; Available from: <https://www.un.org/development/desa/publications/world-population-prospects-the-2017-revision.html>.
2. Moßhammer, D., et al., *Polypharmazie – Tendenz steigend, Folgen schwer kalkulierbar, Polypharmacy—an upward trend with unpredictable effects*. Dtsch Arztebl Int 2016. 113(38): p. 627-33.
3. Laroche, M.L., et al., *Inappropriate medications in the elderly*. Clin Pharmacol Ther, 2009. 85(1): p. 94-7.
4. Kuramatsu, J.B., et al., *Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage*. JAMA, 2015. 313(8): p. 824-36.
5. Kämmerer, P.W. and B. Al-Nawas, *Zahnärztliche Chirurgie unter oraler Antikoagulation/Thrombozytenaggregationshemmung - S3-Leitlinie (Langversion) AWMF-Registernummer: 083-018 DGZMK DGMKG 2017*.
6. Kunkel, M., *(Nach)Bluten oder Sterben? – Das Ende eines Mythos in der Antikoagulation*. MKG-Chirurg, 2016. 9: p. 286–288.
7. Wolff, T.F. and K.A. Groetz. *Der Umgang mit antikoagulierten Patienten*. ZMK 2019; Available from: https://www.zmk-aktuell.de/fachgebiete/allgemeine-zahnheilkunde/story/der-umgang-mit-antikoagulierten-patienten_7910.html.
8. Schiegnitz, E. and K.A. Groetz, *AGSMO-Laufzettel empfohlen durch die S3-Leitlinie AR-ONJ (007-091; www.awmf.de), www.agsmo.de oder www.onkosupport.de*. AGSMO.
9. Schiegnitz, E., et al., *S3-Leitlinie: Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ)*. AWMF 007-091, 2018.
10. Chappuis, V., et al., *Medication-related dental implant failure: Systematic review and meta-analysis*. Clin Oral Implants Res, 2018. 29 Suppl 16: p. 55-68.
11. Luo, J.D., et al., *The effect of non-steroidal anti-inflammatory drugs on the osteogenic activity in osseointegration: a systematic review*. Int J Implant Dent, 2018. 4(1): p. 30.
12. Koch, R. *Epidemiologisches Bulletin, aktuelle daten und informationen zu infektionskrankheiten und public health*. 2 2015; Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2015/Ausgaben/05_15.pdf;jsessionid=26F7BFA92A8B5DE3419FAF7F266086EB.2_cid363?_blob=publicationFile.
13. Perez-Castrillon, J.L., et al., *Effect of the antihypertensive treatment on the bone mineral density and osteoporotic fracture*. Curr Hypertens Rev 2005(1): p. 61–66.
14. Pierroz, D.D., et al., *Deletion of beta-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation*. J Bone Miner Res, 2012. 27(6): p. 1252-62.
15. Schlienger, R.G., et al., *Use of beta-blockers and risk of fractures*. JAMA, 2004. 292(11): p. 1326-32.
16. Wu, X., et al., *Antihypertensive Medications and the Survival Rate of Osseointegrated Dental Implants: A Cohort Study*. Clin Implant Dent Relat Res, 2016. 18(6): p. 1171-1182.
17. Mishra, S.K., N.K. Sonnahalli, and R. Chowdhary, *Do antihypertensive medications have an effect on dental implants? A systematic review*. Oral Maxillofac Surg, 2023.

18. De Bruyne, P., et al., *Changes in prescription patterns of acid-suppressant medications by Belgian pediatricians: analysis of the national database, [1997-2009]*. J Pediatr Gastroenterol Nutr, 2014. 58(2): p. 220-5.
19. Mazer-Amirshahi, M., et al., *Rising rates of proton pump inhibitor prescribing in US emergency departments*. Am J Emerg Med, 2014. 32(6): p. 618-22.
20. Targownik, L.E., et al., *Use of proton pump inhibitors and risk of osteoporosis-related fractures*. CMAJ, 2008. 179(4): p. 319-26.
21. O'Connell, M.B., et al., *Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial*. Am J Med, 2005. 118(7): p. 778-81.
22. Wu, X., et al., *Proton Pump Inhibitors and the Risk of Osseointegrated Dental Implant Failure: A Cohort Study*. Clin Implant Dent Relat Res, 2017. 19(2): p. 222-232.
23. Chrcanovic, B.R., et al., *Intake of Proton Pump Inhibitors Is Associated with an Increased Risk of Dental Implant Failure*. Int J Oral Maxillofac Implants, 2017. 32(5): p. 1097-1102.
24. Haney, E.M., et al., *Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men*. Arch Intern Med, 2007. 167(12): p. 1246-51.
25. Carr, A.B., et al., *Relationship between Selective Serotonin Reuptake Inhibitors and Risk of Dental Implant Failure*. J Prosthodont, 2019.
26. Chrcanovic, B.R., et al., *Is the intake of selective serotonin reuptake inhibitors associated with an increased risk of dental implant failure?* Int J Oral Maxillofac Surg, 2017.
27. Bera, R.N., et al., *Implant survival in patients with neuropsychiatric, neurocognitive, and neurodegenerative disorders: A meta-analysis*. Natl J Maxillofac Surg, 2021. 12(2): p. 162-170.
28. Chandra, P., et al., *Role of Selective Serotonin Reuptake Inhibitors in Prognosis Dental Implants: A Retrospective Study*. J Pharm Bioallied Sci, 2021. 13(Suppl 1): p. S92-S96.